UNSPSC 51183600: Antidiabetic and hyperglycemic peptide hormones

This classification denotes hormones synthesized from amino acids, substances called peptide hormones, that help regulate blood glucose levels, thus the term ANTIDIABETIC AND HYPERGLYCEMIC PEPTIDE HORMONES.

UNSPSC 51183600 Antidiabetic and hyperglycemic peptide hormones is a Class code covering injectable diabetes medications and related peptide-based therapeutics that state and local health agencies procure for public facilities, clinics, and patient-assistance programs. Based on recent solicitation activity, state and local buyers source these products through cooperative purchasing agreements that consolidate demand across multiple jurisdictions and establish pricing with manufacturers and authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body visible in recent activity, operating on behalf of participating state and local government facilities across multiple states including Oregon. Procurement under this code emphasizes compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and vendors must maintain relationships with authorized wholesalers and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats.

The code shows limited recent activity concentrated in the upper Midwest and Pacific Northwest. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. The RFP does not disclose specific award values but establishes performance expectations including a 3 percent administrative fee on all purchases, required insurance coverage including $5 million commercial general liability per occurrence, and performance penalties of $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines. The two-year initial contract term includes optional MMCAP-discretionary extensions, and evaluation prioritizes price competitiveness at 75 percent weight, with the remaining 25 percent distributed among fixed pricing format, administrative compliance, EDI capability, and administrative-fee acceptance.